Tango Therapeutics delivers the next generation of precision medicine to people with cancer that leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/17/2020 | Series B-1 | $51.18MM | $xx.xx | $30.58B | Boxer Capital, Casdin Capital, Cormorant Asset Management, Gilead Sciences | |
Price per Share
$xx.xx
Shares Outstanding
27,152,255
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Casdin Capital, Cormorant Asset Management, Gilead Sciences
|
||||||
04/09/2020 | Series B | $60MM | $xx.xx | $17B | Boxer Capital, Casdin Capital, Cormorant Asset Management | |
Price per Share
$xx.xx
Shares Outstanding
45,372,050
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Casdin Capital, Cormorant Asset Management
|
||||||
03/30/2017 | Series A | $55.7MM | $xx.xx | $7.09B | Third Rock Ventures | |
Price per Share
$xx.xx
Shares Outstanding
55,700,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Third Rock Ventures
|